The National Institute of Health (NIH) in the United States has found that Bharat Biotech’s COVAXIN vaccine generates antibodies that effectively neutralize both Alpha and Delta variants of COVID-19. The top health research institute said that an adjuvant developed with funding from the NIH has contributed to the success of the “highly efficacious” COVAXIN COVID-19 vaccine, which roughly 25 million people have received to date in India and elsewhere.
► Subscribe to The Economic Times for latest video updates. It’s free! – http://www.youtube.com/TheEconomicTimes?sub_confirmation=1
► More Videos @ ETTV – http://economictimes.indiatimes.com/TV
► For business news on the go, download ET app:
https://etapp.onelink.me/tOvY/EconomicTimesApp
Follow ET on:
► Facebook – https://www.facebook.com/EconomicTimes
► Twitter – http://www.twitter.com/economictimes
► LinkedIn – http://www.linkedin.com/company/economictimes
► Instagram – https://www.instagram.com/the_economic_times
► Flipboard – https://flipboard.com/@economictimes
source
